Al-Ramadhani Salma, Sai-Giridhar Priya, George Dilushana, Gopinath Preethi, Arkoumani Evdokia, Jader Samar, Sundaresan Maryse, Salgado Roberto, Larsimont Dennis, Bustin Stephen A, Sundaresan Vasi
Cellular Pathology, Princess Alexandra Hospital NHS Trust, Harlow, Essex CM20 1QX, UK.
Int J Mol Sci. 2013 Jun 24;14(7):12931-52. doi: 10.3390/ijms140712931.
Nodal status is one of the most important prognostic factors in breast cancer. Established tests such as touch imprint cytology and frozen sections currently used in the intra-operative setting show variations in sensitivity and specificity. This limitation has led to the development of molecular alternatives, such as GeneSearch, a commercial intra-operative real-time quantitative Polymerase Chain Reaction (RT-qPCR) assay that allows the surgeon to carry out axillary clearance as a one-step process. Since GeneSearch has been discontinued, we have developed the replacement Metasin assay, which targets the breast epithelial cell markers CK19 and mammaglobin mRNA and identifies metastatic disease in sentinel lymph nodes. The optimised assay can be completed within 32 min (6 min for RNA preparation and 26 min instrument run time), making its use feasible in the intraoperative setting. An analysis by Metasin of 154 archived lymph node homogenates previously analysed by both parallel histology and GeneSearch showed concordance for 148 cases. The sensitivity and specificity of Metasin compared with GeneSearch were 95% (CI 83%-99%) and 97% (CI 91%-99%) respectively; compared with histology they were 95% (CI 83%-99%) and 97% (CI 91%-99%), respectively. The sensitivity and specificity of GeneSearch compared with histology were 90% (CI 77%-96%) and 97% (CI 93%-99%) respectively. The positive predictive value of Metasin was 90% and negative predictive value was 98% for both histology and GeneSearch. The positive predictive value of GeneSearch was 92% and the negative predictive value was 97% compared to histology. The discordance rates of Metasin with both GeneSearch and histology were 3.89%. In comparison, the discordance rate of GeneSearch with histology was 4.5%. Metasin's robustness was independently evaluated on 193 samples previously analysed by GeneSearch from the Jules Bordet Institute, where Metasin yielded comparable results.
淋巴结状态是乳腺癌最重要的预后因素之一。目前在术中使用的诸如触摸印片细胞学和冰冻切片等既定检测方法,在敏感性和特异性方面存在差异。这种局限性促使了分子替代方法的发展,例如GeneSearch,这是一种商业化的术中实时定量聚合酶链反应(RT-qPCR)检测方法,可使外科医生将腋窝清扫作为一个步骤完成。由于GeneSearch已停产,我们开发了替代的Metasin检测方法,该方法靶向乳腺上皮细胞标志物CK19和乳腺珠蛋白mRNA,并可识别前哨淋巴结中的转移性疾病。优化后的检测方法可在32分钟内完成(RNA制备6分钟,仪器运行时间26分钟),使其在术中环境中可行。对154份先前经平行组织学和GeneSearch分析的存档淋巴结匀浆进行的Metasin分析显示,148例结果一致。与GeneSearch相比,Metasin的敏感性和特异性分别为95%(95%置信区间83%-99%)和97%(97%置信区间91%-99%);与组织学相比,分别为95%(95%置信区间83%-99%)和97%(97%置信区间91%-99%)。与组织学相比,GeneSearch的敏感性和特异性分别为90%(90%置信区间77%-96%)和97%(97%置信区间93%-99%)。Metasin对组织学和GeneSearch的阳性预测值均为90%,阴性预测值均为98%。与组织学相比,GeneSearch的阳性预测值为92%,阴性预测值为97%。Metasin与GeneSearch和组织学的不一致率均为3.89%。相比之下,GeneSearch与组织学的不一致率为4.5%。对来自朱尔斯·博尔德研究所的193份先前经GeneSearch分析的样本独立评估了Metasin的稳健性,Metasin得出了可比结果。